I have a similar avg buyin.
However, I still expect Neuren management to do their utmost to realise the full value and not leave money on the table.
This means $200+ from what I can see.
It's certainly hard to see how any deal at that level could happen from where we are at the moment.
For that reason Neuren management may have no alternative but to take NNZ-2591 through to FDA approval. Of course, if successful in all 3 indications we'll then be talking about 4-8x Reata or more like $500 a share.
Either way it would be negligent for them to do a deal that substantially undervalues Neuren. The boards obligation isn't just to those that bought at $2. They have the same obligation to realise maximum value to those that bought at $25.
I certainly agree it's hard waiting tho...
(20min delay)